Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronic Acid as Adjuvant Treatment of Triple-negative Breast Cancer
NCT02595138Phase 3Unknown
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- Oct 2015
- Primary completion
- Oct 2018
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of zoledronic acid in triple-negative breast cancer (TNBC), sponsored by Chinese Academy of Medical Sciences. Status: unknown.
02
Drugs
zoledronic acid
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02595138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02595138.